Most MedTech marketing problems get misdiagnosed. The message is rarely the thing that is broken. What is missing is the operational layer underneath it.
A medical device marketing strategy is usually judged by what people can see: the website, the booth, the sales deck, the claims on the one-pager. When results disappoint, that visible layer is what gets rebuilt. New positioning, new brand, new copy. Six months later the numbers look about the same.
The reason is structural. More than 80% of medical technology firms in the United States have fewer than 50 employees.1 At that size, marketing is one or two people who inherited the CRM, the claims review process, the lead routing, and the sales handoff along with the campaign calendar. Visible work gets attention because it is visible. The operational work underneath it gets deferred until something breaks.
That deferral compounds. A brand clinicians trust is not the product of better adjectives. It is the product of a company that answers consistently, documents what it is allowed to say, and does not lose a qualified inquiry somewhere between a form fill and a rep.
The following post breaks down what a medical device marketing strategy has to carry, why the failure usually sits below the message, and the specific infrastructure to build before the next campaign goes out.
In most B2B categories, marketing generates demand and hands it to sales. In MedTech, marketing has to satisfy four audiences with different questions, and the four answers have to agree with each other.
The clinician wants to know whether the device fits their patients and their workflow. The health system wants to know what it costs, what it displaces, and who supports it. The payer wants evidence tied to a covered indication. The FDA governs what any of those statements are allowed to say in the first place.
A medical device marketing strategy is the system that keeps those four answers consistent as the company grows. That is a documentation and process problem before it is a creative one. Cicada, a MedTech launch partner, spends most of its time on this layer because it is where launches quietly stall, and it is the foundation of how we do it.
Four patterns show up repeatedly in medtech brand strategy work, and each one gets misread as a copy problem.
The website says one thing, the sales deck says another, and a conference abstract says a third. There is no single source of truth for cleared indications, so every asset was written from memory.
Inquiries arrive, get logged, and are never worked. That is a routing and ownership failure, not a demand failure.
Reps rebuild materials because the existing library does not answer the objections they actually hear, and nothing captures that feedback.
Campaign spend is not connected to opportunities, so budget decisions get made on impression. Rewriting the message does not fix any of these four. A better sentence delivered through a broken system is still a broken system.
This is where medical device marketing compliance separates MedTech from every other category. A 510(k) clearance means the FDA found the device substantially equivalent to a legally marketed predicate device, with the same intended use and no different questions of safety and effectiveness.2 It is not an endorsement and it is not a performance claim.
The more consequential point for marketers sits in the regulation itself. Intended use is established by objective evidence, and advertising matter along with the oral and written statements of company representatives counts as that evidence.3 Marketing does not simply describe a device's intended use. It helps define it.
That makes the claims boundary an operational asset rather than a style guide. It needs a document stating the cleared indication verbatim, an approved-language list, a review path with a named owner, and a version history. Companies that keep this in one person's head lose it the moment that person leaves or a rep improvises in the field.
The FDA authorized 124 novel medical devices in 2025, one of the highest annual totals in the Center for Devices and Radiological Health's more than 40 year history.4 Every one of those companies now has to keep a growing set of external statements aligned with a fixed regulatory boundary. That takes a system, not a habit.
Brand in MedTech is largely the accumulated memory of how a company behaved. Did the follow-up arrive? Did the second conversation know what happened in the first? Did the clinical question reach someone who could answer it? Those are CRM questions before they are brand questions.
The industry data supports the concern. In Greenlight Guru's 2025 survey of more than 500 medical device professionals, 56% still relied on paper-based or general-purpose tools for clinical data, and 62% of large companies reported struggling with siloed data.5 The tooling gap is documented, and it does not stop at the quality system.
Before a campaign runs, commercial infrastructure should already answer four questions: where an inquiry lands, who owns it, what happens in the first 24 hours, and what gets written to the record when it converts. A campaign launched against unanswered versions of those questions produces activity, not pipeline.
In launch work, failures cluster at three seams rather than inside any single function. Naming the seams is what makes them fixable.
A lead arrives as a form fill with no context: no account, no procedure volume, no existing purchasing relationship. The rep starts from zero, and after enough of those, stops trusting the source entirely.
A physician asks something outside the approved-language list. With no defined escalation path, the rep either guesses or goes quiet, and both outcomes cost the account.
The evidence that persuades a clinician is not the evidence that persuades a payer or a value analysis committee. When those teams work in sequence instead of in parallel, the economic argument gets written after the buying conversation has already happened. This is why a medical device reimbursement strategy belongs inside the commercial plan rather than beside it. None of the three seams is a talent problem. Each one is a process that was never written down.
Sequence matters more than sophistication. In order:
1. The claims file. Cleared indication, approved language, review owner, version log. Nothing external ships before this exists.
2. The CRM baseline. Accounts, contacts, lead source, stage definitions, and one owner per record. Simple and consistently used beats sophisticated and ignored.
3. The core asset set. One clinical one-pager, one economic one-pager, one objection guide, and one site packet. Built once, reviewed once, used everywhere.
4. The handoff rules. Written definitions of who receives what, when, and what triggers an escalation.
5. Then campaigns.
Measurement follows the same logic. Impressions and traffic describe the top of the system. The numbers that describe whether the system works are response time to inbound inquiry, share of leads with a named owner, opportunities by source, sales cycle length by account type, and the ratio of approved to improvised claims showing up in the field. Those belong on the same dashboard as pipeline.
A medical device marketing strategy is the plan and the operating system for reaching clinicians, health systems, and payers with consistent, compliant claims. It covers positioning and messaging, and it also covers the claims documentation, CRM structure, lead routing, and team handoffs that let those messages survive contact with a real buying process.
Regulation defines what can be said. Under FDA rules, advertising and the statements of company representatives are evidence of a device's intended use, so marketing language carries regulatory consequence. The buying group is also larger, typically including a clinician, a value analysis committee, and a finance or supply chain owner, each evaluating on different criteria.
Before clearance. The claims file, CRM structure, and asset library take months to build properly and are much harder to assemble under launch pressure. Companies that wait for the clearance letter usually spend the first two quarters after it building what should already have existed.
Promotion of a device that is not yet cleared or approved is restricted, and any pre-clearance communication needs regulatory review. Most of the groundwork is still available: category education, clinical relationships, brand and website foundations, and CRM buildout. Have your regulatory lead or counsel define the line before anything goes out.
Track operational metrics alongside demand metrics. Inbound response time, share of leads with a named owner, opportunities by source, and sales cycle length by account type tell you whether the system functions. Impressions and traffic only tell you the top of the funnel is busy.
A medical device marketing strategy gets judged on the visible layer and determined by the invisible one. Clinicians and health systems decide whether to trust a company based on whether it answers consistently, follows up reliably, and says the same thing in every room it enters. None of that is a copywriting outcome.
Write the claims file. Structure the CRM. Define the handoffs. Then put the message on top of something built to hold it. You can see what that looks like across launches in our case studies.
Related reading: Post-Clearance Commercialization: Why the Work Has to Start Before Your Letter Arrives
Cicada is a MedTech launch partner that helps FDA-cleared companies bridge the gap between clearance and commercial success. Through market access messaging, KOL engagement programs, operational support, brand development, and precision-driven market expansion, Cicada aligns marketing, sales, and operations to build revenue-ready healthcare companies. Learn more at cicada.co or see how we do it.
1 AdvaMed. "Job Creation." https://www.advamed.org/medical-device-industry-facts/job-creation/
2 U.S. Food and Drug Administration. "Premarket Notification 510(k)." https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k
3 Code of Federal Regulations. "21 CFR 801.4: Meaning of intended uses." https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-801/subpart-A/section-801.4
4 U.S. Food and Drug Administration. "CDRH Annual Report 2025." 2025. https://www.fda.gov/media/190779/download
5 Greenlight Guru. "2025 Medical Device Industry Report." https://www.greenlight.guru/state-of-medical-device
We work with commercially-viable health technology companies that are ready to scale. If that sounds like you, let's talk.
Schedule a Call